• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacotherapy of pompholyx.

作者信息

Wollina Uwe, Abdel Naser Mohamed Badawy

机构信息

Academic Teaching Hospital Dresden Friedrichstadt, Department of Dermatology, Friedrichstrasse 41, 01067 Dresden, Germany.

出版信息

Expert Opin Pharmacother. 2004 Jul;5(7):1517-22. doi: 10.1517/14656566.5.7.1517.

DOI:10.1517/14656566.5.7.1517
PMID:15212602
Abstract

Pompholyx is an inflammatory vesicobullous disorder of the palms and soles. The condition is difficult to treat because of the peculiarities of the affected skin, namely, the thick horny layer and richness of sweat glands. The cornerstones of topical therapy are corticosteroids, although calcineurin inhibitors seem to be effective as well. Topical photochemotherapy with 8-methoxypsoralen is as effective as systemic photochemotherapy or high-dose ultra violet Type A-1 irradiation. Systemic therapy is often necessary in bullous pompholyx. Corticosteroids are used commonly, although no controlled studies have been published. For recalcitrant cases corticosteroids are combined with immunosuppressants. A new evolving treatment seems to be the intradermal injection of botulinum toxin.

摘要

相似文献

1
Pharmacotherapy of pompholyx.
Expert Opin Pharmacother. 2004 Jul;5(7):1517-22. doi: 10.1517/14656566.5.7.1517.
2
Pompholyx: a review of clinical features, differential diagnosis, and management.水疱性湿疹:临床特征、鉴别诊断及治疗的综述。
Am J Clin Dermatol. 2010;11(5):305-14. doi: 10.2165/11533250-000000000-00000.
3
Pompholyx: what's new?汗疱疹:有什么新进展?
Expert Opin Investig Drugs. 2008 Jun;17(6):897-904. doi: 10.1517/13543784.17.6.897.
4
Topical khellin and natural sunlight in the outpatient treatment of recalcitrant palmoplantar pompholyx: report of an open pilot study.外用凯林与自然阳光用于顽固性掌跖汗疱疹的门诊治疗:一项开放性初步研究报告
Dermatology. 2005;211(4):381-3. doi: 10.1159/000088517.
5
Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx.
J Am Acad Dermatol. 1999 Apr;40(4):612-4. doi: 10.1016/s0190-9622(99)70446-9.
6
Pompholyx of the hands after intravenous immunoglobulin therapy for clinically isolated syndrome: a paediatric case.静脉注射免疫球蛋白治疗临床孤立综合征后手部汗疱疹:儿科病例。
Int J Immunopathol Pharmacol. 2014 Jan-Mar;27(1):127-30. doi: 10.1177/039463201402700117.
7
Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison.辅助性肉毒杆菌毒素A治疗汗疱疹型手部湿疹:一项采用左右对比的对照前瞻性试点研究。
J Eur Acad Dermatol Venereol. 2002 Jan;16(1):40-2. doi: 10.1046/j.1468-3083.2002.00361.x.
8
Dupilumab in the Treatment of Dyshidrosis: A Report of Two Cases.度普利尤单抗治疗汗疱疹:两例报告
J Drugs Dermatol. 2018 Mar 1;17(3):355-356.
9
Pompholyx with bile-coloured vesicles in a patient with jaundice: are sweat ducts involved in the development of pompholyx?
J Eur Acad Dermatol Venereol. 2010 Feb;24(2):235-6. doi: 10.1111/j.1468-3083.2009.03383.x. Epub 2009 Aug 16.
10
[Pompholyx-like reactions occurring early in treatment of severe atopic dermatitis in children and adolescence].
Arerugi. 2011 Nov;60(11):1543-9.

引用本文的文献

1
The key role of aquaporin 3 and aquaporin 10 in the pathogenesis of pompholyx.水通道蛋白3和水通道蛋白10在汗疱疹发病机制中的关键作用。
Med Hypotheses. 2015 May;84(5):498-503. doi: 10.1016/j.mehy.2015.02.006. Epub 2015 Feb 11.
2
["With all suitable means". Off-label-use and public statutory employers' liability insurance].["采取一切适当手段"。药品未按说明书使用与公共法定雇主责任保险]
Hautarzt. 2013 Oct;64(10):743-7. doi: 10.1007/s00105-013-2592-3.
3
Peat: a natural source for dermatocosmetics and dermatotherapeutics.泥炭:皮肤美容和皮肤治疗的天然来源。
J Cutan Aesthet Surg. 2009 Jan;2(1):17-20. doi: 10.4103/0974-2077.53094.
4
The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.美国食品药品监督管理局(FDA)针对局部用钙调神经磷酸酶抑制剂的“黑框”警告:争议仍在继续。
Drug Saf. 2008;31(3):185-98. doi: 10.2165/00002018-200831030-00001.